Annals of medicine and surgery (2012) · 2025
Assessment of safety of niraparib maintenance therapy in epithelial ovarian cancer: an updated systematic review and meta-analysis of randomized control trials.
СтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Khan Muhammad Saad, Khalid Maliha, Farhan Kanza, Chandani Harshika Khaim, Ansari Osaid Ahmed, Chandani Devya Khaim, Khalid Dua, Memon Usama, Waafira Aminath
Аннотация
INTRODUCTION: Patients with epithelial ovarian cancer (EOC) who are treated with niraparib maintenance therapy, experience hematological and gastrointestinal side effects. There is a scarcity of evidence on the safety of niraparib. This study aims to assess the safety profile of niraparib as a maintenance treatment for women with platinum-sensitive EOC.
METHODS: PubMed (Medline), EMBASE, and Google Scholar were searched for randomized controlled trials (RCTs) with people suffering from EOC. This study used Review Manager and forest plots for visual display. Random effects models were used for this meta-analysis (RRs and 95% CIs).
RESULTS: The study analyzed 2311 cases from 7/8 RCTS of niraparib-treated patients with high risks of any grade of anemia (RR, 3.51; 95% CI, 2.99 to 4.10, P < 0.00001) and thrombocytopenia (RR, 13.28; 95% CI, 10.00 to 17.63, P < 0.00001). For grade 3 or 4 adverse effects, significantly higher risk was only noted for thrombocytopenia (RR, 32.80; 95% CI, 10.63 to 101.22, P < 0.00001), anemia (RR, 14.45; 95% CI, 6.48 to 32.27, P < 0.00001) for niraparib-treated patients. Less treatment-related deaths occurred.
CONCLUSION: There is a need to emphasize on cautious use, hematological toxicities, and personalized dosage regimens of niraparib for improved patient compliance.
METHODS: PubMed (Medline), EMBASE, and Google Scholar were searched for randomized controlled trials (RCTs) with people suffering from EOC. This study used Review Manager and forest plots for visual display. Random effects models were used for this meta-analysis (RRs and 95% CIs).
RESULTS: The study analyzed 2311 cases from 7/8 RCTS of niraparib-treated patients with high risks of any grade of anemia (RR, 3.51; 95% CI, 2.99 to 4.10, P < 0.00001) and thrombocytopenia (RR, 13.28; 95% CI, 10.00 to 17.63, P < 0.00001). For grade 3 or 4 adverse effects, significantly higher risk was only noted for thrombocytopenia (RR, 32.80; 95% CI, 10.63 to 101.22, P < 0.00001), anemia (RR, 14.45; 95% CI, 6.48 to 32.27, P < 0.00001) for niraparib-treated patients. Less treatment-related deaths occurred.
CONCLUSION: There is a need to emphasize on cautious use, hematological toxicities, and personalized dosage regimens of niraparib for improved patient compliance.